March 13, 2026. 6 articles reviewed below the CED clinical relevance threshold of 35. Listed in descending order of score.
A Beginner’s Guide to Reading Cannabis Certificates of Analysis in Florida
This article explains how to interpret cannabis testing documentation in Florida, which may interest clinicians tracking product quality standards and cannabinoid concentrations relevant to patient recommendations.
Read more →BOS commercial cannabis amendments proposed – Lake County Record-Bee
Lake County proposes amendments to commercial cannabis regulations originally established a decade ago, reflecting regulatory evolution in the industry.
Read more →Police Officers Who Tested Positive for Cannabis Sue Jersey City Seeking Return of Firearms
Three terminated Jersey City police officers seek firearm return after positive cannabis tests, raising questions about cannabis testing policies and employment consequences in law enforcement.
Read more →Trulieve to Open Medical Cannabis Dispensary in DeLand, Florida – Stock Titan
This article reports on Trulieve’s expansion of medical cannabis dispensary locations in Florida, which may interest clinicians tracking retail cannabis availability and market developments in their region.
Read more →Bipartisan Senate Bill Would Create Psychedelic-Focused VA Research Centers To Explore …
# Article Summary A bipartisan Senate bill proposes VA research centers for psychedelics, reflecting broader federal interest in alternative therapeutic compounds alongside cannabis in addressing veteran health outcomes.
Read more →Tenet Healthcare Corporation $THC Stock Position Decreased by First Trust Advisors LP
# Summary First Trust Advisors LP reduced its investment position in Tenet Healthcare Corporation by 31.5% in Q3, representing routine institutional portfolio management activity with no direct cannabis clinical relevance.
Read more →Digest-Level Clinical Commentary
# Clinical Reflection These items collectively signal three concurrent pressures reshaping cannabis medicine practice: regulatory fragmentation (Florida’s emphasis on cannabinoid ratios and Lake County’s evolving amendments) suggests practitioners must increasingly counsel patients on product standardization amid inconsistent state frameworks, while employment disputes and stock volatility indicate the field remains institutionally precarious and underintegrated into mainstream healthcare infrastructure. The psychedelic research momentum suggests cannabis medicine may be losing relative priority in clinical research funding and policy attention, even as dispensary expansion continues. For evidence-based practice, this underscores the urgent need for robust pharmacokinetic guidance and employment protections that match the pace of commercialization.
# Clinical Perspective These items reflect several concurrent developments in cannabis and psychedelic policy and clinical practice. There is ongoing regulatory standardization occurring at state and local levels, particularly around product testing and dispensary operations, while employment and legal frameworks continue to evolve regarding cannabis use among specific populations such as law enforcement. Additionally, there appears to be emerging clinical and research interest in psychedelic therapeutics at the federal level, suggesting a broader shift in how medical institutions may approach these substances in controlled research settings.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: